Switzerland· 67900003
Wilentin 300 mg, Hartkapseln
A trientine product, registered in Switzerland by Future Health Pharma GmbH and dispensed under Swissmedic category B. The same ATC class is registered in 19 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Trientine is registered in 19 of 19 countries.
Countries holding a registration under ATC A16AX12 (trientine), each read from that country’s own register.
- This record: Switzerland
- 11 of them publish a price we can compare per daily dose
Trientine · ATC A16AX12
19 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of trientine costs, country by country.
Normalised to the WHO defined daily dose (0.45 g), the median price runs from $97.54 in Switzerland to $186.45 in Italy — a ×1.9 gap.
- Switzerland: $97.54 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Trientine · price per daily dose (0.45 g)
USD · FX 28 Sept 2026
- IT Italy$186.45
- CH Switzerland$97.54
The record
At a glance
- Manufacturer
- Future Health Pharma GmbH
- Country
- Switzerland (CH)
- ATC code
- A16AX12
- ATC class
- Trientine
- Defined daily dose
- 0.45 g, O
- Swissmedic category
- B
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
35 interactions on record for trientine.
Graded by severity as the source publishes them — 31 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Trientine · interactions on record
35 records
- 31 moderate
- 4 minor
Most severe, free to view
- Magnesium carbonateA02AA01moderate
- Magnesium oxideA02AA02moderate
- Magnesium hydroxideA02AA04moderate
- Kombinationen von AluminiumsalzenA02AB10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A16AX12
Trientine, as other registers publish it.
- GermanyAvelerisIdeogen Gmbh
- BelgiumAveleris 167 mgIdeogen
- IrelandAveleris 167 mg hard capsulesIdeogen GmbH
- IrelandAveleris 167 mg hard capsulesTillomed Pharma GmbH
- NetherlandsAveleris 167 mg harde capsulesIdeogen GmbH
- FinlandCufenceUnivar Solutions BV
- PolandCufenceUnivar Solutions BV
- PolandCufenceUnivar Solutions BV
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf2c60ae-8d94-4f81-913c-9b480f8821c2 GET /v1/drugs/bf2c60ae-8d94-4f81-913c-9b480f8821c2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about trientine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.